The total revenue generated by the digital biomarkers market in 2021 was USD 1,850.8 million, and it will advance at a compound annual growth rate of 31.6% in the years to come, to reach USD 21,986.2 million by 2030, according to a market research report, published by P&S Intelligence.
Digital biomarkers are the substance of precision medicine since they offer concrete evidence of patient outcomes.
Furthermore, the healthcare system is moving in the direction of a value-based delivery paradigm, spurred the expansion of state-of-the-art technologies, for example digital biomarkers. The key goal of developing such technology is to advance custom-made care delivery through an improved analysis of patients’ healthcare info.
The increasing occurrence of cardiovascular diseases because of many causes, including high consumption of tobacco, bad eating habits, and extreme alcoholism, will fuel the development of this in the future. Digital biomarkers take in the patient data and improve patient care and outcomes of the treatment.
APAC dominated the digital biomarkers market, with regards to revenue, and it will continue its dominance in the years to come. Recently, the increasing government expenditure on the expansion of cutting-edge healthcare infra has significantly boosted the acceptance of digital biomarkers in the APAC.
The propagation of digital technologies and their snowballing acceptance in the healthcare sector are driving the growth.
China is quickly growing because of the budding acceptance of internet connectivity, mobile phones, and digital health techs, which opened up new pathways for improving non-transmissible disease care delivery and population health management.
Due to the increasing use of smartphones and internet, the demand for digital biomarkers will continue to grow significantly by the end of this decade.
No comments:
Post a Comment